TG-4050
- Generic Name
- TG-4050
A Clinical Trial Evaluating TG4050 in Head and Neck Cancer
- First Posted Date
- 2019-12-03
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Transgene
- Target Recruit Count
- 80
- Registration Number
- NCT04183166
- Locations
- 🇺🇸
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
🇫🇷Hôpital Saint André - CHU de Bordeaux, Bordeaux, France
🇫🇷Hôpital de la Timone, Marseille, France
A Trial Evaluating TG4050 in Ovarian Carcinoma.
Phase 1
Completed
- Conditions
- Peritoneal CarcinomaOvarian CarcinomaFallopian Tube Cancer
- Interventions
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Transgene
- Target Recruit Count
- 64
- Registration Number
- NCT03839524
- Locations
- 🇫🇷
IUCT Toulouse, Toulouse, France
🇺🇸Mayo Clinic Rochester, Rochester, Minnesota, United States
🇫🇷Hôpital Pitié-Salpêtrière, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath